Latest Contracts News

Alcidion Group Limited has reversed a significant loss from the previous year, reporting a $1.65 million profit for FY25 driven by new sales and a leaner cost base.

Air New Zealand reported a resilient $126 million net profit for FY2025 despite grounding up to 11 aircraft due to engine maintenance issues, while advancing its net zero emissions commitment with a new 2030 guidance.

IGO Limited has reported a dramatic downturn in its financial results for the year ended June 2025, with revenue plunging 60% and a net loss nearing $1 billion. The company also suspended dividends as net tangible assets per share fell sharply.

Macquarie Technology Group Limited reported solid FY25 results with continued EBITDA growth and strong cash conversion, underpinned by strategic investments in data centre capacity and AI capabilities.

NextEd Group Limited reported a 13.9% revenue decline to $95.9 million for FY25 but achieved a 53% improvement in net loss after tax, driven by cost savings and operational efficiencies. The company’s strategic repositioning includes leadership changes and expanded vocational offerings.

Thorney Opportunities Ltd posted a sharp 76% decline in profit after tax for FY2025 yet declared a higher fully franked final dividend and reported growth in net tangible assets per share.

Shriro Holdings reported a 13.6% revenue decline to $103.3 million in FY25 but delivered a 5.5% rise in EBITDA and an 8.7% increase in net profit after tax. The company completed a $15 million share buy-back and deferred its final dividend as it explores alternative capital uses.

GenusPlus Group Ltd has delivered record FY2025 financial results, driven by strong contract wins and strategic acquisitions, positioning itself as a key player in Australia’s energy transition. The company forecasts robust earnings growth for FY2026 backed by a $2 billion orderbook.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Enlitic, Inc. reported a sharp revenue increase driven by migration services and subscription growth, while sustaining a net loss of US$6.86 million in H1 2025. The company secured a binding MOU with GE Healthcare and completed a A$10 million capital raise.

SIV Capital Limited reported a statutory loss of $112,789 for the year ended June 2025, continuing its operational scale-down with only four active rental contracts. The company remains debt-free with $8.18 million in cash but its ASX securities remain suspended as it evaluates a confidential corporate opportunity.